p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs

WAF1, a potential mediator of p53 tumor suppression

1993 • 8,360 citations

p53, the Cellular Gatekeeper for Growth and Division

1997 • 7,621 citations

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1984 • 6,841 citations

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry

1991 • 4,682 citations

Participation of p53 protein in the cellular response to DNA damage.

1991 • 3,818 citations

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia

1992 • 3,092 citations

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1993 • 2,969 citations

p53 is required for radiation-induced apoptosis in mouse thymocytes

1993 • 2,911 citations

Thymocyte apoptosis induced by p53-dependent and independent pathways

1993 • 2,322 citations

Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.

1994 • 2,141 citations

Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control

1995 • 2,115 citations

Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

1995 • 2,028 citations

Definition of a consensus binding site for p53

1992 • 2,000 citations

Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

1992 • 1,877 citations

Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis

1989 • 1,739 citations

Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)

1995 • 1,662 citations

Apoptosis in cancer therapy: Crossing the threshold

1994 • 1,351 citations

Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line

1979 • 1,305 citations

Radiation-induced cell cycle arrest compromised by p21 deficiency

1995 • 1,249 citations

p21 is necessary for the p53-mediated G1 arrest in human cancer cells.

1995 • 1,193 citations

A role for CD95 ligand in preventing graft rejection

1995 • 1,184 citations

Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

1996 • 1,001 citations

Interaction of the p53-Regulated Protein Gadd45 with Proliferating Cell Nuclear Antigen

1994 • 941 citations

Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?

1996 • 917 citations

Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity

1979 • 912 citations

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

1996 • 894 citations

Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53

1990 • 801 citations

Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents.

1993 • 770 citations

Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

1997 • 749 citations

Wild-type p53 can inhibit oncogene-mediated focus formation.

1989 • 738 citations

Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression

1995 • 736 citations

Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer.

1996 • 708 citations

Structure and Function of the p53 Tumor Suppressor Gene: Clues for Rational Cancer Therapeutic Strategies

1996 • 666 citations

Bax suppresses tumorigenesis and stimulates apoptosis in vivo

1997 • 648 citations

p53 modulation of TFIIH–associated nucleotide excision repair activity

1995 • 555 citations

Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene.

1994 • 465 citations

Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover.

1996 • 464 citations

The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells.

1997 • 456 citations

Cyclin G is a transcriptional target of the p53 tumor suppressor protein.

1994 • 450 citations

P53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features

1992 • 448 citations

Human lung carcinomas express Fas ligand.

1997 • 395 citations

CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance

1996 • 394 citations

Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia

1986 • 380 citations

CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.

1997 • 375 citations

Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage.

1995 • 365 citations

Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene.

1996 • 365 citations

Antitumor effect of locally produced CD95 ligand

1997 • 315 citations

Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents

1993 • 305 citations

COMMENTARY: p⁵³ Tumor suppressor gene: from the basic research laboratory to the clinic—an abridged historical perspective

1996 • 284 citations

Sensitization of Cancer Cells Treated With Cytotoxic Drugs to Fas-Mediated Cytotoxicity

1997 • 284 citations

Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens.

1992 • 282 citations

A functional p53-responsive intronic promoter is contained within the humanmdm2gene

1995 • 271 citations

p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines

1993 • 242 citations

A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.

1989 • 190 citations

Taxol induction of p21WAF1 and p53 requires c-raf-1.

1995 • 187 citations

Structure of the human APO‐1 gene

1994 • 165 citations

Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes.

1993 • 152 citations

Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer

1996 • 140 citations

p53-mediated apoptosis in HeLa cells can be overcome by excess pRB.

1995 • 136 citations

Absence of Radiation-induced G1 Arrest in Two Closely Related Human Lymphoblast Cell Lines That Differ in p53 Status

1995 • 136 citations

Identification of p53 target genes through immune selection of genomic DNA: the cyclin G gene contains two distinct p53 binding sites.

1995 • 132 citations

p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta.

1997 • 130 citations

A temperature-sensitive mutant of human p53.

1994 • 128 citations

Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium.

1984 • 127 citations

Transcription Stimulation of the Fas-encoding Gene by Nuclear Factor for Interleukin-6 Expression upon Influenza Virus Infection

1995 • 103 citations

Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis.

1994 • 97 citations

Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells.

1995 • 90 citations

Shifting the cancer paradigm: must we kill to cure?

1995 • 74 citations

APO-1(CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines

1995 • 68 citations

Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion

1993 • 61 citations

Identification of a Silencer, Enhancer, and Basal Promoter Region in the Human CD95 (Fas/APO-1) Gene

1995 • 57 citations

Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells

1997 • 52 citations

Pharmacokinetics ofcis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions

1996 • 47 citations

Expression of Apo‐1/Fas (CD95), Bcl‐2, Bax and Bcl‐x in myeloma cell lines: relationship between responsiveness to anti‐Fas mab and p53 functional status

1997 • 46 citations

Induction of apoptosis by tamoxifen-activation of a p53-estrogen receptor fusion protein expressed in E1A and T24 H-ras transformed p53-/- mouse embryo fibroblasts.

1996 • 43 citations

Bleomycin clinical pharmacology by radioimmunoassay

1982 • 34 citations

Localization of a growth suppressor activity in MCF7 breast cancer cells to chromosome 17q24-q25

1997 • 28 citations

The capacity for growth stimulation by TGF beta 1 seen only in advanced colon cancers cannot be ascribed to mutations in APC, DCC, p53 or ras.

1994 • 27 citations

p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line.

1998 • 26 citations